Phase 2 N=6 Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
DIRA
Primary: Number of Subjects Who Maintained Inflammatory Remission With Rilonacept — 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)
Muscular Dystrophies
Primary: Mean Change From Baseline in Muscle Function Using the 6 Minute Walking Distance — -10.98; -19.93; 16.12 Meters — p=0.554
Phase 2 N=101 Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
Human Immunodeficiency Virus (HIV)
Primary: Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV in the First 21 Days After Vaccine Administration Days in…
Phase 2 N=89 A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
Chronic Hepatitis C · Hepatitis C Virus · Compensated Cirrhosis
Primary: Maximal Decrease From Baseline in log10 HCV RNA Levels During ABT-493 or ABT-530 Monotherapy Treatment — -4.11; -4.02; -4.31; -4.06 Log10 IU/mL
Phase 2 N=25 A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo
Dermatitis, Atopic
Primary: Change From Baseline Three Item Severity (TIS) Scores Between GW870086 (0.2% and 2%) Versus Placebo at Day 22 — -1.99; -2.49; -1.61; -3.11 Score on scale — p=0.480
Phase 2 N=16 Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Refractory Multiple Myeloma
Primary: PFS — 4; 1 Participants
Phase 2 N=14 Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
Neoplasms, Head and Neck
Primary: Number of Participants Achieving Best Overall Response — 7; 3; 1 Participants
Phase 2 N=10 Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study
Facial Rhytids
Primary: Blinded Assessment: Overall Change in Facial Wrinkles From Baseline to Week 2 as Assessed by a Numeric Rating Scale Based on Pre- and Post-treatment Photographs — -0.21…
Phase 2 N=79 Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Gastroparesis
Primary: Gastric Half Emptying Time (GEt1/2) — 131.2; 106.5; 118.2; 131.1 Minutes
Phase 2 N=40 Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Psoriasis
Primary: Assessment of Clinical Activity by Improvement Score (Using Krueger Criteria): Number of Participants With Good or Excellent Improvement Score Based on Histological…
Phase 2 N=163 A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
Follicular Lymphoma
Primary: Percentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission…
Phase 2 N=40 Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Overall Response Rate — 37 Participants
Phase 2 N=24 Aerosol Inhalation Treatment for Dyspnea - Patients
Dyspnea
Primary: Change in Subject Rating of Breathing Discomfort (Dyspnea) Before and After Treatment. — -1.86; -0.61; -0.15 units on a scale — p=0.35
Phase 2 N=31 Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
Atopic Dermatitis
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) — 70.0; 57.1; 40.0; 28.6 percentage of participants
Phase 2 N=192 A Study of MDT-10013 in the Treatment of Acute Postoperative Pain Following Bunionectomy
Postoperative Pain
Primary: Summed Pain Intensity Over 1- 48hrs (SPI-48) From Cohort 1 to 3 — 252.29; 213.28; 191.97; 215.35 units on a scale